Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Alnylam Pharmaceuticals Stock Forecast NASDAQ:ALNY
Price Target and Analyst Ratings
Historical Ratings
| Date | Upside / Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 2022-05-02 | 244.36% | HC Wainwright & Co. | $400.00 $430.00 | Maintains | Buy |
| 2022-04-29 | 36.14% | Morgan Stanley | $178.00 $170.00 | Maintains | Equal-Weight |
| 2022-04-29 | 68.98% | Citigroup | $223.00 $211.00 | Maintains | Buy |
| 2022-04-29 | 32.94% | BMO Capital | $171.00 $166.00 | Maintains | Market Perform |
| 2022-04-29 | -23.12% | SVB Leerink | $103.00 $96.00 | Maintains | Market Perform |
| 2022-04-25 | 42.55% | Morgan Stanley | $210.00 $178.00 | Downgrades | Overweight Equal-Weight |
| 2022-04-12 | 220.33% | HC Wainwright & Co. | $350.00 $400.00 | Maintains | Buy |
| 2022-03-01 | 78.59% | Citigroup | $223.00 | Initiates Coverage On | Buy |
| 2022-02-23 | 68.17% | Morgan Stanley | $215.00 $210.00 | Maintains | Overweight |
| 2022-02-11 | -17.51% | SVB Leerink | $109.00 $103.00 | Maintains | Market Perform |
| 2022-02-03 | 36.14% | Guggenheim | $170.00 | Upgrades | Neutral Buy |
| 2022-01-28 | -12.71% | SVB Leerink | $108.00 $109.00 | Maintains | Market Perform |
| 2022-01-20 | 180.29% | HC Wainwright & Co. | $250.00 $350.00 | Maintains | Buy |
| 2022-01-18 | 72.18% | Morgan Stanley | $226.00 $215.00 | Maintains | Overweight |
| 2022-01-03 | 66.57% | Piper Sandler | $181.00 $208.00 | Upgrades | Neutral Overweight |
| 2021-11-22 | 80.19% | RBC Capital | $144.00 $225.00 | Upgrades | Sector Perform Outperform |
| 2021-11-22 | 118.63% | Goldman Sachs | $273.00 | Upgrades | Neutral Buy |
| 2021-11-22 | 64.17% | Needham | $180.00 $205.00 | Maintains | Buy |
| 2021-11-01 | 60.17% | Oppenheimer | $200.00 | Upgrades | Perform Outperform |
| 2021-10-29 | 80.99% | Morgan Stanley | $242.00 $226.00 | Maintains | Overweight |
| 2021-10-29 | 60.17% | Chardan Capital | $190.00 $200.00 | Maintains | Buy |
| 2021-10-28 | -13.51% | SVB Leerink | $104.00 $108.00 | Maintains | Market Perform |
| 2021-10-12 | 93.8% | Morgan Stanley | $234.00 $242.00 | Maintains | Overweight |
| 2021-10-04 | 72.18% | UBS | $141.00 $215.00 | Upgrades | Neutral Buy |
| 2021-08-27 | 56.96% | BMO Capital | $174.00 $196.00 | Maintains | Market Perform |
| 2021-08-13 | 100.21% | HC Wainwright & Co. | $235.00 $250.00 | Maintains | Buy |
| 2021-08-04 | 87.39% | Morgan Stanley | $224.00 $234.00 | Maintains | Overweight |
| 2021-08-04 | 72.98% | Barclays | $196.00 $216.00 | Maintains | Overweight |
| 2021-08-04 | 44.95% | Piper Sandler | $181.00 | Downgrades | Overweight Neutral |
| 2021-07-16 | 79.39% | Morgan Stanley | $205.00 $224.00 | Maintains | Overweight |
| 2021-04-30 | 64.17% | Morgan Stanley | $206.00 $205.00 | Maintains | Overweight |
| 2021-02-22 | 29.73% | Guggenheim | $162.00 | Downgrades | Buy Neutral |
| 2021-02-12 | 64.97% | Morgan Stanley | $203.00 $206.00 | Maintains | Overweight |
| 2021-02-12 | 56.96% | Barclays | $162.00 $196.00 | Maintains | Overweight |
| 2021-02-12 | 40.15% | Citigroup | $170.00 $175.00 | Downgrades | Buy Neutral |
| 2021-02-12 | 88.2% | HC Wainwright & Co. | $225.00 $235.00 | Maintains | Buy |
| 2021-02-12 | 44.15% | Needham | $160.00 $180.00 | Maintains | Buy |
| 2021-01-25 | 48.15% | BMO Capital | $185.00 | Downgrades | Outperform Market Perform |
| 2020-11-25 | 62.57% | Morgan Stanley | $200.00 $203.00 | Maintains | Overweight |
| 2020-11-25 | -25.52% | SVB Leerink | $91.00 $93.00 | Maintains | Market Perform |
| 2020-11-24 | -27.12% | SVB Leerink | $90.00 $91.00 | Maintains | Market Perform |
| 2020-11-06 | 60.17% | Morgan Stanley | $197.00 $200.00 | Maintains | Overweight |
| 2020-10-15 | 25.73% | B of A Securities | $160.00 $157.00 | Maintains | Buy |
| 2020-09-08 | 36.14% | Citigroup | $170.00 | Initiates Coverage On | Buy |
| 2020-08-11 | 24.93% | Oppenheimer | $162.00 $156.00 | Downgrades | Outperform Perform |
| 2020-08-07 | 57.76% | Morgan Stanley | $199.00 $197.00 | Maintains | Overweight |
| 2020-08-07 | -27.93% | SVB Leerink | $89.00 $90.00 | Maintains | Market Perform |
| 2020-07-15 | 59.37% | Morgan Stanley | $162.00 $199.00 | Maintains | Overweight |
| 2020-05-28 | -2.3% | UBS | $111.00 $122.00 | Maintains | Neutral |
| 2020-05-13 | 20.12% | RBC Capital | $150.00 | Initiates Coverage On | Sector Perform |
| 2020-05-07 | 24.93% | Barclays | $143.00 $156.00 | Maintains | Overweight |
| 2020-05-07 | 36.94% | BMO Capital | $145.00 $171.00 | Maintains | Outperform |
| 2020-05-07 | 29.73% | Oppenheimer | $140.00 $162.00 | Maintains | Outperform |
| 2020-05-07 | 29.73% | Morgan Stanley | $148.00 $162.00 | Maintains | Overweight |
| 2020-05-07 | 9.71% | JP Morgan | $133.00 $137.00 | Downgrades | Overweight Neutral |
| 2020-05-06 | 28.13% | Needham | $135.00 $160.00 | Maintains | Buy |
| 2020-04-14 | -40.74% | Nomura | $74.00 $74.00 | Maintains | Reduce |
| 2020-03-19 | 60.17% | Berenberg | $200.00 | Initiates Coverage On | Buy |
| 2020-02-11 | -39.94% | Nomura | $62.00 $75.00 | Maintains | Reduce |
| 2020-02-07 | 18.52% | Morgan Stanley | $150.00 $148.00 | Maintains | Overweight |
| 2019-12-19 | 52.16% | Chardan Capital | $150.00 $190.00 | Maintains | Buy |
| 2019-12-18 | 40.95% | Cantor Fitzgerald | $159.00 $176.00 | Reiterates | Overweight |
| 2019-12-17 | 20.12% | Morgan Stanley | $141.00 $150.00 | Maintains | Overweight |
| 2019-11-25 | 14.52% | BMO Capital | $138.00 $143.00 | Maintains | Outperform |
| 2019-11-21 | 4.91% | Barclays | $125.00 $131.00 | Maintains | Overweight |
| 2019-11-21 | 27.33% | Cantor Fitzgerald | $150.00 $159.00 | Maintains | Overweight |
| 2019-11-21 | 12.92% | Morgan Stanley | $124.00 $141.00 | Maintains | Overweight |
| 2019-11-21 | 10.51% | BMO Capital | $128.00 $138.00 | Maintains | Outperform |
| 2019-11-20 | 2.51% | Oppenheimer | $128.00 | Initiates Coverage On | Outperform |
| 2019-11-13 | -11.91% | B of A Securities | $110.00 | Initiates Coverage On | Buy |
| 2019-09-04 | -23.12% | UBS | $95.00 $96.00 | Maintains | Neutral |
| 2019-09-03 | 16.12% | Piper Sandler | $142.00 $145.00 | Maintains | Overweight |
| 2019-08-07 | -0.7% | Morgan Stanley | $126.00 $124.00 | Maintains | Overweight |
| 2019-05-23 | -35.93% | Goldman Sachs | $80.00 | Assumes | Neutral |
ALNY Stock Trend
The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $119.24 is broken, it will firstly indicate a stronger fall rate.
Given the current short-term trend, the stock is expected to fall -13.00% during the next 3 months and, with a 90% probability hold a price between $103.74 and $137.04 at the end of this 3-month period.
WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2022-05-18 | $118.85 | $137.99 | $157.12 |
| 2022-05-19 | $118.46 | $137.59 | $156.73 |
| 2022-05-20 | $118.07 | $137.20 | $156.34 |
| 2022-05-23 | $117.67 | $136.81 | $155.95 |
| 2022-05-24 | $117.28 | $136.42 | $155.55 |
| 2022-05-25 | $116.89 | $136.03 | $155.16 |
| 2022-05-26 | $116.50 | $135.63 | $154.77 |
| 2022-05-27 | $116.11 | $135.24 | $154.38 |
| 2022-05-31 | $115.71 | $134.85 | $153.99 |
| 2022-06-01 | $115.32 | $134.46 | $153.59 |
| 2022-06-02 | $114.93 | $134.07 | $153.20 |
| 2022-06-03 | $114.54 | $133.67 | $152.81 |
| 2022-06-06 | $114.15 | $133.28 | $152.42 |
| 2022-06-07 | $113.75 | $132.89 | $152.02 |
| 2022-06-08 | $113.36 | $132.50 | $151.63 |
| 2022-06-09 | $112.97 | $132.10 | $151.24 |
| 2022-06-10 | $112.58 | $131.71 | $150.85 |
| 2022-06-13 | $112.18 | $131.32 | $150.46 |
| 2022-06-14 | $111.79 | $130.93 | $150.06 |
| 2022-06-15 | $111.40 | $130.54 | $149.67 |
| 2022-06-16 | $111.01 | $130.14 | $149.28 |
| 2022-06-17 | $110.62 | $129.75 | $148.89 |
| 2022-06-21 | $110.22 | $129.36 | $148.50 |
| 2022-06-22 | $109.83 | $128.97 | $148.10 |
| 2022-06-23 | $109.44 | $128.58 | $147.71 |
| 2022-06-24 | $109.05 | $128.18 | $147.32 |
| 2022-06-27 | $108.66 | $127.79 | $146.93 |
| 2022-06-28 | $108.26 | $127.40 | $146.53 |
| 2022-06-29 | $107.87 | $127.01 | $146.14 |
| 2022-06-30 | $107.48 | $126.61 | $145.75 |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The companys clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR); ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; Fitusiran, an... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 108 000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
